Karyopharm Therapeutics Inc.
NASDAQ:KPTIBiotechnology
-$0.34 today
- Market cap
- $158.87M
- Beta
- 0.82
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$8.86
Volume 0.67M
Average 0.85M
Income Statement
Follow revenue through to earnings.
Revenue
$146.07M
FY 2025 · Annual
+0.6% YoYOperating Income
-$90.71M
FY 2025 · Annual
Net Income
-$196.04M
FY 2025 · Annual
Income Statement
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 209.82M | 157.07M | 146.03M | 145.24M | 146.07M |
| Cost of Revenue | 3.4M | 5.21M | 4.94M | 6.01M | 5.95M |
| Gross Profit | 206.42M | 151.86M | 141.09M | 139.23M | 140.12M |
| Gross Margin | 98.4% | 96.7% | 96.6% | 95.9% | 95.9% |
| Research & Development | 160.84M | 148.66M | 138.75M | 143.23M | 125.62M |
| Selling, General & Admin | 143.85M | 145.4M | 131.88M | 115.44M | 105.21M |
| Operating Expenses | 304.69M | 294.06M | 270.63M | 258.67M | 230.83M |
| Depreciation & Amortization | 789K | 621K | 530K | 340K | 296K |
| EBITDA | (96.99M) | (139.31M) | (118.42M) | (38.6M) | (149.85M) |
| EBITDA Margin | -46.2% | -88.7% | -81.1% | -26.6% | -102.6% |
| Operating Income | (98.27M) | (142.2M) | (129.54M) | (119.44M) | (90.71M) |
| Operating Margin | -46.8% | -90.5% | -88.7% | -82.2% | -62.1% |
| Interest Income | 582K | 2.36M | 10.94M | 7.4M | 2.77M |
| Interest Expense | 26.05M | 25M | 23.82M | 37.42M | 45.85M |
| Other Income / Expenses | (25.55M) | (22.72M) | (13.24M) | 43.08M | (105.29M) |
| Income Before Tax | (123.82M) | (164.92M) | (142.78M) | (76.37M) | (196M) |
| Pre-Tax Margin | -59.0% | -105.0% | -97.8% | -52.6% | -134.2% |
| Income Tax Expense | 268K | 369K | 323K | 57K | 43K |
| Net Income | (124.09M) | (165.29M) | (143.1M) | (76.42M) | (196.04M) |
| Net Margin | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% |
| EPS (Basic) | (24.75) | (30.28) | (18.79) | (9.41) | (17.93) |
| EPS (Diluted) | (24.75) | (30.28) | (18.79) | (9.41) | (17.93) |
| 5.01M | 5.46M | 7.61M | 8.12M | 10.94M | |
| 5.01M | 5.46M | 7.61M | 8.12M | 10.94M |
KPTI Earnings Waterfall · TTM
NASDAQ:KPTI · Revenue to Net Income
Key Ratios
Analysis
$151.1M of revenue converted into -$195.0M of net income for the selected period. Gross margin is 96.1% and net margin is -134.3%, showing how much revenue survives after costs and taxes. EPS is $-15.07, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Jul 17, 2026 | |
| SC 13G/A | SC 13G/A filing | Jun 5, 2026 | |
| 8-K | Current report | May 28, 2026 | |
| S-8 | S-8 filing | May 27, 2026 | |
| S-8 | S-8 filing | May 27, 2026 |
How much revenue does KPTI generate?
Karyopharm Therapeutics Inc. (KPTI) reported $146.07M of revenue in fiscal 2025.
Is KPTI profitable?
Karyopharm Therapeutics Inc. (KPTI) reported -$196.04M of net income, with a net margin of -134.2%.
Continue the stock analysis
Jump to another research area for this company.